These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8987168)

  • 21. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline.
    Manrique RV; Manrique V
    Angiology; 1987 Feb; 38(2 Pt 1):101-8. PubMed ID: 3030162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of platelet aggregation by prostacyclin is attenuated after exercise in patients with angina pectoris.
    Kishi Y; Ashikaga T; Numano F
    Am Heart J; 1992 Feb; 123(2):291-7. PubMed ID: 1736562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human serum, plasma, and platelets stimulate prostacyclin and endothelin-1 synthesis in human vascular endothelial cells.
    Mikkola T; Ristimäki A; Viinikka L; Ylikorkala O
    Life Sci; 1993; 53(3):283-9. PubMed ID: 8321089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of prostacyclin on the coagulation of whole blood.
    Holloway DS; Zuckerman L; Vagher JP; Mockros LF
    Thromb Haemost; 1983 Oct; 50(3):671-5. PubMed ID: 6359571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clot-promoting effect of platelet-vessel wall interaction: influence of dietary fats and relation to arterial thrombus formation in rats.
    Hornstra G; Hemker HC
    Haemostasis; 1979; 8(3-5):211-26. PubMed ID: 389757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of prostacyclin in vascular tissue.
    Moncada S; Vane JR
    Fed Proc; 1979 Jan; 38(1):66-71. PubMed ID: 215463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased platelet sensitivity to prostacyclin (epoprostenol) during hemodialysis.
    Kristensen SD; Knudsen F; Nielsen AH; Ring T
    Clin Nephrol; 1984 Apr; 21(4):230-4. PubMed ID: 6375926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet derived growth factor (PDGF) and prostaglandins (PGE1, PGI2) as modulators of the atherogenetic process.
    Sinzinger H; Zidek T; Fitscha P; Kaliman J; Steurer G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(4):439-42. PubMed ID: 2465948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beneficial effects of prostacyclin in a rabbit endotoxin shock model.
    Ditter H; Matthias FR; Voss R; Lohmann E
    Thromb Res; 1988 Aug; 51(4):403-15. PubMed ID: 3055416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostacyclin (epoprostenol) as the sole antithrombotic agent in postdilutional hemofiltration.
    Canaud B; Mion C; Arujo A; N'Guyen QV; Paleyrac G; Hemmendinger S; Cazenave JP
    Nephron; 1988; 48(3):206-12. PubMed ID: 2965311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discrimination between platelet-mediated and coagulation-mediated mechanisms in a model of complex thrombus formation in vivo.
    Cadroy Y; Horbett TA; Hanson SR
    J Lab Clin Med; 1989 Apr; 113(4):436-48. PubMed ID: 2522978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of prostacyclin on platelet intracellular free calcium concentration of hypertensive and normotensive humans.
    Komura H; Bukoski RD; Karanja N; Morris CD; Shingu T; McCarron DA
    Am J Hypertens; 1993 Sep; 6(9):730-5. PubMed ID: 8110425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor.
    Coughlin SR; Moskowitz MA; Zetter BR; Antoniades HN; Levine L
    Nature; 1980 Dec; 288(5791):600-2. PubMed ID: 7003399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human prostacyclin platelet receptors in diabetes mellitus.
    Modesti PA; Fortini A; Gensini GF; Vanni D; Prisco D; Abbate R
    Thromb Res; 1991 Sep; 63(5):541-8. PubMed ID: 1755006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitric oxide and prostacyclin modulate the alterations in cardiac action potential duration mediated by platelets during ischaemia.
    Goulielmos NV; Enayat ZE; Sheridan DJ; Cohen H; Flores NA
    Cardiovasc Res; 1995 Nov; 30(5):788-98. PubMed ID: 8595628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug stimulated prostacyclin release.
    Weithmann KU
    Ric Clin Lab; 1981; 11 Suppl 1():209-14. PubMed ID: 6324324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nitric oxide complements prostacyclin in the regulation of endothelial thromboresistance under flow conditions.
    Korbut R; Ocetkiewicz A; Gryglewski RJ
    Methods Find Exp Clin Pharmacol; 1993 Apr; 15(3):179-81. PubMed ID: 8332034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostacyclin-synthesis stimulating plasma factor and platelet sensitivity in preeclampsia.
    Dadak C; Kefalides A; Sinzinger H
    Biol Res Pregnancy Perinatol; 1985; 6(2):65-9. PubMed ID: 3893552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translocation-independent activation of protein kinase C by platelet-activating factor, thrombin and prostacyclin. Lack of correlation with polyphosphoinositide hydrolysis in rabbit platelets.
    Salari H; Duronio V; Howard S; Demos M; Pelech SL
    Biochem J; 1990 May; 267(3):689-96. PubMed ID: 2160234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Platelet-stimulated thrombin and PDGF are normalized by insulin and Ca2+ channel blockers.
    Kahn NN
    Am J Physiol; 1999 May; 276(5):E856-62. PubMed ID: 10329979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.